Neogenomics Inc.
NEO
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.16B
Close$
$-11.23
167.7% downside
Current Fair Value
167.7% downsideOvervalued by 167.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.16 Billion |
|---|---|
| Enterprise Value | $2.46 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.84 |
| Beta | 1.78 |
| Outstanding Shares | 129,628,000 |
Return
| Return on Equity | -6.60% |
|---|---|
| Return on Assets | -3.84% |
| Return on Invested Capital | -3.65% |
Valuation & Multiples
| P/E Ratio | -41.81 |
|---|---|
| PEG | 39.83 |
| Price to Sales | 3.32 |
| Price to Book Ratio | 2.77 |
| Enterprise Value to Revenue | 3.21 |
| Enterprise Value to EBIT | -54.2 |
| Enterprise Value to Net Income | -48 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$196.95 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$206.70 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 0.59% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.29%▼ 558.71% |
|---|---|
| Total Invested | $25.07M▼ 98.82% |
| Investors Holding | 47▼ 231.00% |
ESG Score
No data
About Neogenomics Inc.
1,600 employeesNeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...